Compare Natera Inc. Common Stock (NTRA) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Tidewater Inc — how do they compare? Natera Inc. Common Stock trades at $394.16 (market cap $57.03B), while Tidewater Inc trades at $83.01 (market cap $4.33B). The key difference: Natera Inc. Common Stock is far larger — about 13.2× Tidewater Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Tidewater Inc for 27 Days on average.
| NTRA | TDW | |
|---|---|---|
Market Cap | $57.03B | $4.33B |
Volume | 1,131,157 | 553,078 |
Sector | Health | Energy |
52-Week High | $425.64 | $100.61 |
52-Week Low | $179.42 | $47.29 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $56.18B | $4.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Tidewater (TDW) trades at $86.97, up 0.6% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $105.50. The company reported strong 2025 results with $1.35B revenue and $334.66M net income, though recent quarterly earnings have missed expectations. Positive developments include the completion of the Wilson Sons Ultratug acquisition in August 2026 and a significant $503.2M investment from BlackRock.
The stock offers potential upside to the price target, driven by operational strength and strategic acquisitions. Key risks include earnings volatility, competitive pressures in the energy sector, and exposure to geopolitical tensions affecting day rates. Investor sentiment is mixed, with 30.77% of analysts rating it a buy amid recent insider selling and institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
